Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine

H Chaytow, KME Faller, YT Huang… - Cell Reports Medicine, 2021 - cell.com
Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease that, in the
most severe cases and when left untreated, leads to death within the first two years of life …

Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions

JK Nussbacher, R Tabet, GW Yeo, C Lagier-Tourenne - Neuron, 2019 - cell.com
RNA binding proteins are critical to the maintenance of the transcriptome via controlled
regulation of RNA processing and transport. Alterations of these proteins impact multiple …

Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy

CJ Lumpkin, AW Harris, AJ Connell, RW Kirk… - Scientific Reports, 2023 - nature.com
Proximal spinal muscular atrophy (SMA) is a leading genetic cause for infant death in the
world and results from the selective loss of motor neurons in the spinal cord. SMA is a …

Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities

L Servais, G Baranello, M Scoto, A Daron… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative
neuromuscular disease that presents primarily in children. Abnormalities in the SMN1 gene …

NADPH oxidase 4 inhibition is a complementary therapeutic strategy for spinal muscular atrophy

M El Khoury, O Biondi, G Bruneteau… - Frontiers in Cellular …, 2023 - frontiersin.org
Introduction Spinal muscular atrophy (SMA) is a fatal neurodegenerative disorder,
characterized by motor neuron (MN) degeneration and severe muscular atrophy and caused …

[HTML][HTML] Anti-prion drugs targeting the protein folding activity of the ribosome reduce PABPN1 aggregation

A Bamia, M Sinane, R Naït-Saïdi, J Dhiab, M Keruzoré… - …, 2021 - Elsevier
Prion diseases are caused by the propagation of PrP Sc, the pathological conformation of
the PrP C prion protein. The molecular mechanisms underlying PrP Sc propagation are still …

Understanding the Role of the SMN Complex Component GEMIN5 and Its Functional Relationship with Demethylase KDM6B in the Flunarizine-Mediated …

B Salman, E Bon, P Delers, S Cottin… - International …, 2024 - search.proquest.com
Dysregulated RNA metabolism caused by SMN deficiency leads to motor neuron disease
spinal muscular atrophy (SMA). Current therapies improve patient outcomes but achieve no …

Accumulation of poly (A) RNA in nuclear granules enriched in Sam68 in motor neurons from the SMNΔ7 mouse model of SMA

JO Narcís, O Tapia, O Tarabal, L Piedrafita, J Calderó… - Scientific reports, 2018 - nature.com
Spinal muscular atrophy (SMA) is a severe motor neuron (MN) disease caused by the
deletion or mutation of the survival motor neuron 1 (SMN1) gene, which results in reduced …

A link between agrin signalling and Cav3.2 at the neuromuscular junction in spinal muscular atrophy

P Delers, D Sapaly, B Salman, S De Waard… - Scientific Reports, 2022 - nature.com
SMN protein deficiency causes motoneuron disease spinal muscular atrophy (SMA). SMN-
based therapies improve patient motor symptoms to variable degrees. An early hallmark of …

The small-molecule flunarizine in spinal muscular atrophy patient fibroblasts impacts on the gemin components of the SMN complex and TDP43, an RNA-binding …

D Sapaly, P Delers, J Coridon, B Salman… - Frontiers in Molecular …, 2020 - frontiersin.org
The motor neurodegenerative disease spinal muscular atrophy (SMA) is caused by
alterations of the survival motor neuron 1 (SMN1) gene involved in RNA metabolism …